Showing results (51-60 of 63) with videos related to
Sort By:
Pageof 7
Bioorganic & Medicinal Chemistry Letters|January 5, 1999
Dibasic benzo[b]thiophene derivatives as a novel class of active site directed thrombin inhibitors. 2. Exploring interactions at the proximal (S2) binding siteD J Sall, S L Briggs, N Y Chirgadze, et al.Bioorganic & Medicinal Chemistry Letters|October 31, 2000
1,2-Disubstituted indole, azaindole and benzimidazole derivatives possessing amine moiety: a novel series of thrombin inhibitorsK Takeuchi, J A Bastian, D S Gifford-Moore, et al.Bioorganic & Medicinal Chemistry Letters|October 6, 1999
The design of potent, selective, non-covalent, peptide thrombin inhibitors utilizing imidazole as a S1 binding elementM R Wiley, L C Weir, S L Briggs, et al.Seminars in Thrombosis and Hemostasis|January 1, 1996
A family of arginal thrombin inhibitors related to efegatranG F Smith, R T Shuman, T J Craft, et al.Journal of Medicinal Chemistry|November 30, 2013
Controlled-deactivation cannabinergic ligandsRishi Sharma, Spyros P Nikas, Carol A Paronis, et al.Bioorganic & Medicinal Chemistry Letters|September 6, 2005
Investigation of factor Xa inhibitors containing non-amidine S1 elementsJeffry B Franciskovich, John J Masters, Jennifer M Tinsley, et al.Journal of Medicinal Chemistry|December 4, 2014
Probing the carboxyester side chain in controlled deactivation (-)-δ(8)-tetrahydrocannabinolsSpyros P Nikas, Rishi Sharma, Carol A Paronis, et al.Bioorganic & Medicinal Chemistry Letters|November 3, 2007
Investigation of the terminal P4 domain in a series of D-phenylglycinamide-based factor Xa inhibitorsJeffry B Franciskovich, John J Masters, Wayne W Weber, et al.Bioorganic & Medicinal Chemistry|April 8, 2020
Design and optimization of a series of 4-(3-azabicyclo[3.1.0]hexan-3-yl)pyrimidin-2-amines: Dual inhibitors of TYK2 and JAK1Andrew Fensome, Catherine M Ambler, Eric Arnold, et al.Bioorganic & Medicinal Chemistry Letters|April 14, 1999
Dibasic benzo[b]thiophene derivatives as a novel class of active site directed thrombin inhibitors: 2. Sidechain optimization and demonstration of in vivo efficacyM Zhang, D L Bailey, J A Bastian, et al.Pageof 7